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Herein we report a library of new ruthenium(II) complexes which 
incorporate a range of functionalised -ketoiminate ligands. The 
complexes undergo an unusual reduction from Ru(III) to Ru(II), 
and consequently incorporate carbonyl ligands from the 2-
ethoxyethanol solvent, forming ruthenium dicarbonyl complexes. 
In order to address the potential applications of these complexes, 
we have screened the library against a range of tumour cell lines, 
however, all compounds exhibit low cellular activity and this is 
tentatively assigned to the decomposition of the compounds in 
aqueous media. Studies to establish the antifungal and 
antibacterial potential of these complexes was addressed and 
show increased growth inhibitions for C. neoformans and S. 
aureus species. 
Transition metal coordination complexes are some of the most 
promising anti-cancer drugs to date, with many complexes 
showing selective potency both in vitro and in vivo.1,2 
However, due to the potential of multiple isomers, there 
remains issues with such complexes in terms of their 
intracellular isomerisation and instability in aqueous media. 
This was highlighted during the clinical Phase trials of 
budotitane, cis-[(EtO)2(bzac)2Ti] (bzac = benzoylacetone) 
(Figure 1A),3 which exhibited high in vivo activity but Phase I 
trials were terminated due to severe adverse side-effects and 
issues with formulation.4 We have also reported similar 
titanium complexes, [(X)2(bzacR)2Ti] (Figure 1B), which 
undergo ligand exchange and more than one isomer is 
observed in solution. The cellular testing of the compounds 
has been terminated, due to issues with determining the 
active species.5,6 
After platinum-based drugs, ruthenium complexes are the 
second most promising class of therapeutics. The first known 
ruthenium complexes to be investigate, were the analogues of 
cisplatin, in which Clarke et al. reported the anticancer activity 
of fac-[Cl3(NH3)3Ru] (Figure 1C).7 However, further work was 
halted on this compound, due to poor solubility and 
formulation issues. Prior to this work, the first reported 
ruthenium halide complex containing DMSO was synthesised 
by James et al. in 1971, whereby they first described the 
synthesis of [Cl2(DMSO)4Ru].8 In 1983, Sava et al. highlighted 
the therapeutic importance of this complex, and reported the 
cis-[Cl2(DMSO)4Ru] (Figure 1D) to have high in vivo potencies, 
which were 3-fold more active than cisplatin.9–11 The results 
led to the synthesis of the trans analogue, trans-
[Cl2(DMSO)4Ru] (Figure 1E), which was found to be ca. 20-fold 
more active than the cis complex against Lewis lung 
carcinoma, a metastasizing murine tumour.12 Unlike the trans 
analogue of cisplatin, transplatin, which remains non-toxic.13  
During this period, Keppler et al. highlighted a ruthenium(III) 
complex, [IndH]trans-[Cl4(Ind)2Ru] (KP1019, Ind = indazole, 
Figure 1F), which exhibited high cellular activity, especially 
against platinum-resistant colorectal autochthonous 
tumours.14 This compound entered Phase I clinical trials, 
showing no serious side-effects and progressed towards Phase 
II trials to elucidate the therapeutic efficacy.15–17 Alongside 
KP1019, the work of Sava et al. highlighted another trans 
ruthenium(III) complex, [ImH]trans-[Cl4(Im)(DMSO)Ru] (NAMI-
A, Im = imidazole, Figure 1G), which is known for its 
antimetastatic properties.18 The complex was able to inhibit 
the growth of in vivo pulmonary metastases solid tumours. 
NAMI-A was in Phase II clinical trials and tested in combination 
with gemcitabine, though the trials were recently terminated 
as the results did not show an improvement on using 
gemcitabine alone.19 
Figure 1 Range of ruthenium coordination compounds which have been shown to have 
high in vitro/ in vivo potency 
To date there have been many promising ruthenium(II) 
coordination complexes and ruthenium(II) arene complexes 
which exhibit high micromolar potency towards cancerous cell 
lines.20 We have previously reported a range of ruthenium(III) 
bis(picolinamide) dihalide complexes, [X2(L)2Ru] (L = 
functionalised picolinamide ligand) (Figure 1H), and have 
shown that the cytotoxicity is dependent of the isomers 
present.21 Additionally, we reported ruthenium and iridium 
arene complexes which incorporate functionalised -
ketoiminate ligands,22–24 and have shown that these 
complexes exhibit low micromolar potency. Therefore, the 
  
work discussed herein aims to combine coordination 
ruthenium complexes with -ketoiminate ligands, to assess 
their ability to form single stable isomers and screen their 
cytotoxicity towards tumour cell lines, fungi and bacteria. 
Synthesis of β-ketoiminato ruthenium(II) complexes 
By treating a functionalised β-ketoiminate ligand (2 eq.), with 
triethylamine (2 eq.) and ruthenium(III) chloride trihydrate (1 
eq.), whilst heating to reflux for 6 h in ethoxyethanol (~100 
eq.), we attempted to synthesise ruthenium bis(β-
ketoiminato)ruthenium(II) chloride complexes, [Cl(L)2Ru]. 
However, from the reaction mixture the ruthenium dicarbonyl 
complexes 1-16 (Scheme 1) were isolated. This synthesis is 
characterised by the reduction of ruthenium in the metal 
precursor from Ru(III) to Ru(II), allowing for NMR analysis, and 
the usual incorporation of terminal carbon monoxide. This was 
initially not expected, and the formation of the carbonyl 
ligands is thought to be a result of the decarbonylation of the 
2-ethoxyethanol acting as the solvent. When comparing to the 
literature, Ammermann et al. reported an iridium(III) complex 
which also incorporated a carbonyl ligand when using 2-
ethoxyethanol.25 Similar to our own conclusions, the research 
group noted that changes in the reagent ratios and solvent did 
not yield the desired ruthenium carbonyl complexes. This 
complex does not undergo a reduction to iridium(II), however, 
using labelled H218O experiments, the oxygen in the carbonyl 
ligand was assigned to that from water, whilst the carbon is 
tentatively assigned to the 2-ethoxyethanol solvent. Although 
unusual, the possibility of the formation of hydride-, carbonyl- 
or hydridocarbonyl-metal complexes when a transition metal 
complex is in contact with an alcoholic medium is well 
documented.26 For example, Chatt et al. have shown that 
ruthenium phosphine complexes can form ruthenium carbonyl 
complexes in alcoholic solvents.27 This synthetic pathway 
yields only moderate yields of 30-43%, which were slightly 
improved by using a slight excess of base. Column 
chromatography (dicholoromethane/hexane) was used to 
purify the crude bis(β-ketoiminate)ruthenium(II) dicarbonyl 
complexes, and yielded complexes 1-16 as yellow-green 
crystalline compounds which are air-stable.  
Scheme 1 Synthesis of bis(β-ketoiminato)ruthenium(II) dicarbonyl complexes 1-16 
Analysis of β-ketoiminato ruthenium(II) complexes 
Complexes 1-16 have been fully characterised by infrared 
spectroscopy, 1H, 13C{1H}, COSY and HMQC spectroscopy, mass 
spectrometry, elemental analysis and single crystal X-ray 
crystallography where appropriate. All complexes show the 
characteristic CO stretches between 1900-2100 cm-1, which 
are consistent with other reported ruthenium carbonyls 
(Figure S1 and Table S6).28 1H NMR spectroscopy was used to 
follow the progress of the reaction, with the loss of the -
ketoiminate ligand NH being the most characteristic change, 
followed by the shift to lower frequencies of the methine 
resonance, from approximately 5.70 ppm (free ligand) to 5.50 
ppm (complex) (Figure S2).  
Single crystals suitable for X-ray diffraction were obtained for 
complexes 1-4, 6-11, 13 and 15 (CCDC numbers: 1940927-
1940938, Table S1-S3), by either vapour diffusion of 
dichloromethane/pentane, or concentrated acetonitrile at 
< 4°C. The complexes crystallised in either a monoclinic (1, 4, 
9-11 and 12), triclinic (2, 3 and 6-8) or orthorhombic (15) space 
group, with molecular structures shown in Figure 2. The 
complexes exhibit pseudo octahedral structures, with the 
ligands’ bond angles in the ranges of 83–96° (cis) and 170-185° 
(trans). The Ru-N(amine) and Ru-O(phenolate) bond lengths 
are within the ranges 2.08-2.10 Å and 2.04-2.10 Å, 
respectively, and are consistent with Ru(II) -ketoiminate 
complexes reported in the literature.22 The Ru-C(carbonyl) 
bond lengths, in the range 1.86-1.88 Å, are slightly longer than 
reported Ru-C bond lengths.29 Characteristic short bond 
lengths, in the range 1.13-1.14 Å are observed for C≡O in all 
complexes and are within reported literature values (Table S4 
(lengths) and Table S5 (angles)).30,31 Unlike our previously 
reported ruthenium(III) bis(picolinamide) complexes, the 
complexes presented herein only crystallise in a cis isomer 
(with respect to the ancillary ligand), with all solid state 
structures showing a cis(CO)-cis(O)-trans(N) arrangement.21 In 
order to address the isomers present in solution, 1H NMR 
spectra were recorded for the complexes between 333K and 
278K (Figure S3 and S4), and show no changes or broadening 
of the resonances at all temperatures. The evidence of single 
stable cis isomers is contrary to our previously published work, 
and is thought to be due to the backdonation of the carbon 
monoxide ligands, which helps to stabilise the cis 
arrangement. The elimination of multiple isomers is a 
significant step forward in producing drug candidates which 
are stable and have fewer issues during formulation, and we 
are conducting additional studies to further understand these 
observations. 
Chemosensitivity Assays under Normoxic Conditions 
The cytotoxicity of complexes 1-16 was evaluated against 
human pancreatic carcinoma (MIA PaCa-2), human colon 
carcinoma (HCT116 p53+/+) and normal human retinal pigment 
epithelial cells (ARPE-19). All of the results show that these 
complexes are either non-toxic or moderately cytotoxic, 
therefore structure activity relationships cannot be fully 
determined (Table 1). There is a slight trend observed, 
whereby the para mono-substituted halide complexes 3 (4’-F), 
6 (4’-Cl) and 8 (4’-Br) have higher potency than other 
complexes in the library. Our previously reported work has 
highlighted the meta fluoro -ketominate ligand to be the  
  
Figure 2 Molecular structures of bis(-ketoiminato)ruthenium(II) carbonyl complexes 1-4, 6-11, 12 and 15. Displacement ellipsoids are at the 50% probability level and hydrogen 
atoms and disordered parts are omitted for clarity. 
 
most promising when complexed to ruthenium, however, the 
results shown herein highlight the para fluoro complex 3 to be 
almost 3 times as potent. Interestingly, our previously 
reported organometallic ruthenium p-cymene complexes with 
these -ketoiminate ligands have cytotoxicity values ranging 
from 3.5-22.0 M (against HT-29), whilst the activity decreases 
by up to 24-fold when the p-cymene ring is removed and 
replaced by another equivalent of the ligand.22,23 
The cytotoxicity of complex 3 is significantly reduced when the 
aniline ring is functionalised with a para fluoro substituent 
(12), and the phenyl ring connected to the keto group remains 
non-functionalized. Complex 12 exhibits a 3-fold decrease in 
potency, when compared to complex 3, highlighting for this 
example that a functionalisation of the benzoyl moiety may 
lead to more potent drugs candidates than a functionalisation 
of the aniline ring. The LogP values of all complexes were 
predicted using ALOGPS (Table S9) and were all found to be 
hydrophobic,32,33 however, no structure activity relationships 
could be determined between LogP and cytotoxicity. 
Chemosensitivity Assays under Hypoxic Conditions 
Due to the abnormal vasculature and microenvironment of 
solid tumours, the use of chemotherapy and radiation cancer 
treatments becomes difficult, as some tumour cells are often 
resistant to treatment.34 An advantage of some inorganic 
complexes is the ability of the metal and/or redox active 
ligands to be activated in low oxygen (reducing) conditions, 
therefore, we have tested the moderately active complex 4 
under hypoxic conditions. This complex was tested alongside 
cisplatin, after 96 hours incubation with the HCT116 p53+/+ cell 
line at 0.1% O2. The results show that the activity of complex 4 
decreases by 2-fold when tested under hypoxic conditions (IC50 
= 21.6 M (21% O2) and 50.5 M (0.1% O2)), whereas the 
activity of cisplatin decreases by 26-fold under the same 
conditions (IC50 = 3.3 M (21% O2) and 95.5 M (0.1% O2). The 
decrease in activity of cisplatin has been associated with the 
activation of autophagy and mediated cisplatin resistance;35 
therefore, complexes with higher activity than cisplatin under 
hypoxic conditions are promising and can provide an 
understanding towards smart synthesis when designing new 
compounds as potential drug candidates. Though the 
ruthenium is highly unlikely to reduce in vitro, these studies 
under low O2 concentration can help to identify complexes 
which remain cytotoxic or can be used in hypoxia 
targeting.36,37 
 
Stability Studies in Aqueous Media 
In order to address the stability of the complexes in aqueous 
conditions, initial samples were set up in 10% DMSO:90% H2O 
  
or D2O to analyse both the UVvis spectra and NMR spectra,38 
however the complexes precipitate out of solution at such high 
water content (Figures 5A and 5B). Samples were then made 
up at varying concentrations of water, and found to only 
remain in solution at 10% H2O. 1H NMR samples were 
prepared in 90% d3-acetonitrile:10% D2O to give a final 
concentration of 8 mg mL-1, and spectra were recorded every 
24 hours over a period of 4 days (Figure S6). Minor changes in 
the 1H NMR spectra are observed from day 0 to day 4, 
whereby the intensity of the resonances decreases, 
particularly in the aromatic (7-8 ppm) and methine β-
ketoiminate proton (5.7-5.9 ppm) regions. The resonance 
corresponding to the methine proton disappears completely 
by day 4, with no broadening of resonances or paramagnetic 
shifts. This suggests the potential hydrolysis of the -
ketoiminate ligands over this period of time, however, there 
are no peaks in the ES-MS which can be assigned to the free 
ligand. The hydrolysis of these -ketominate ligands has 
already been reported by the group when bound to 
ruthenium(II) p-cymene or iridium(III) Cp*.22,24  
Table 1 Chemosensitivity results of complexes 1-16, cisplatin and oxaliplatin against 
MIA-PaCa-2, HCT116 p53+/+ and ARPE-19. Values are stated as inhibition concentrations 
(IC50) ± Standard Deviation (SD) and are triplicate repeats. 
Complex IC50 ± SD (μM) 
 MIA-PaCa-2 HCT116 p53+/+ ARPE-19 
1 89 ± 9 86 ± 22 92 ± 14 
2 >100 65 ± 19 >100 
3 >100 22 ± 4 38 ± 9 
4 >100 >100 >100 
5 >100 >100 >100 
6 96 ± 7 43 ± 6 51 ± 3 
7 >100 96 ± 7 >100 
8 93 ± 12 68 ± 11 82 ± 21 
9 >100 54 ± 14 52 ± 12 
10 61 ± 9 60 ± 7 78 ± 20 
11 81 ± 12 63 ± 8 79 ± 25 
12 92 ± 14 67 ± 7 89 ± 20 
13 >100 72 ± 6 >100 
14 84 ± 19 82 ± 8 91 ± 17 
15 >100 65 ± 16 >100 
16 >100 >100 >100 
cisplatin 3.6 ± 0.7 3.3 ± 0.4 6 ± 1 
oxaliplatin 6 ± 1 0.9 ± 0.1 6 ± 3 
 
Additionally, UV-vis spectra were recorded every 24 hours for 
4 days in 90% acetonitrile and 10% water to give a final 
concentration of 50 μM (Figure S7 and Table S7). The final 
products were analysed by ESI-MS. Slow darkening of the 
initial colour, from yellow to brown, was observed for all 
complexes between days 0 to day 4, with complex 6 showing 
the slowest colour change, with changes observed in the UV-
vis spectra. All complexes convert to a species which is likely to 
be the same in all experiments, whereby the peak at 350-400 
nm has both a bathochromic and hypochromic shift, 
suggestive of a structurally different complex. As observed in 
Table 1, the complexes only have moderate to low anticancer 
activity, and with the complexes studied for hydrolysis, the 
order of anticancer activity is inversely proportional to the rate 
of hydrolysis; 3 > 1 > 6 > 12 > 13 > 9 (Table S8). The hydrolysis 
rates are relatively similar for the unsubstituted complex 1 and 
the electron withdrawing substituted complex 3 suggesting 
that addition of the electron withdrawing substituents on the 
ligand has no significant effect on the rate of hydrolysis. 
Contrary to this, electron donating substituents, such as the 
para methyl group on complex 9, significantly lower the rate of 
hydrolysis. Additionally, the nature of the phenyl ring also 
affects the rate of hydrolysis, whereby complex 3 (para fluoro 
phenyl) is completely hydrolysed by within 24 hours, while 11 
(para fluoro aniline) is only completely hydrolysed by day 4. 
Analogues complexes, 6 (para chloro phenyl) and 13 (para 
chloro aniline) also show comparable results. 
Antifungal and Antibacterial Properties of -ketoiminato 
ruthenium(II) Complexes 
To date there have been few reports on the use of ruthenium 
complexes as anti-fungal agents,39 though activities against 
Aspergillus flavus and fusarium species have been reported for 
ruthenium Schiff base complexes. In collaboration with the CO-
ADD (Community for Antimicrobial Drug Discovery, The 
University of Queensland, Australia), we have evaluated the 
antifungal activities of complexes 1-16 against Candida 
albicans (C. albicans) and Cryptococcus neoformans var. grubii 
(C. neoformans) (Table S10). The complexes showed selectivity 
towards the C. albicans fungal strain as shown by the positive 
growth inhibition values when compared to the negative 
values obtained for C. neoformans, with complex 7 having a 
growth inhibition of 44.1 %, and a selectivity ratio > 18.5. 
Comparing these results to those obtained by Dyson et al. on 
the inhibition properties of ruthenium(II) arene RAPTA-like 
(RAPTA = ruthenium arene 1,3,5-triaza-7-phosphatricyclo-
[3.3.1.1]decane) complexes, our complexes exhibited 
inhibition of C. neoformans which are several orders of 
magnitude higher.40 Though we have not yet identified the 
mechanism of inhibition, we are investigating these complexes 
as carbon monoxide-releasing molecules (CORMs).41 
One of the major advances in the medical field has been the 
development and widespread use of antimicrobials, with 
transition metal complexes receiving significant interest for 
the development of metal based antimicrobial agents.42 The 
ability of fine-tuning the coordination sphere, the oxidation 
state and the possibility of simultaneous multiple mechanisms 
of action, may help to overcome drug resistance.43 As CORMs 
are known to have a different mode of action in their 
biological and therapeutic applications when compared to 
other transition metal based molecules, it has prompted 
investigations into their potential application for the treatment 
of antibiotic-resistant bacteria.44 To assess the potential of our 
complexes, we collaborated with the CO-ADD and screened 
complexes 1-16 against five different antibiotic-resistant 
bacterial strains. Though most of the complexes are inactive 
(Table S11), complex 10 is partially active against Gram-
positive S. aureus species, with a growth inhibition of 58%, and 
  
inactive against the other four bacterial strains, which is again 
an order of magnitude higher than recently reported 
ruthenium(II) arene complexes,40 and similar to other reported 
metallocene complexes.45 
Conclusions 
In this study we have introduced a range of new bis(-
ketominato) ruthenium(II) carbonyl complexes which have an 
unusual reaction pathway. We are currently conducting 
mechanistic work on the understanding of these reactions and 
products. The complexes were screened for their anticancer, 
antimicrobial and antifungal activities, whereby the position of 
the different substituents on the -diketoiminate ligand has a 
significant effect on the complexes’ activity. Though the 
anticancer activities are only moderate, the antifungal and 
antibacterial results are promising for complexes 7 and 10, 
which have increased growth inhibitions for C. neoformans and 
S. aureus species, respectively. The recorded inhibition values 
are several orders of magnitude higher than previously 
reported metal-based complexes. 
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